3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
50
Stomach Neoplasms
7
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
HER2-positive Breast Cancer
3
Esophageal Neoplasms
3
Uterine Neoplasms
2
Solid Tumors
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Compliance
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Interventions
pembrolizumab
35
Cisplatin
12
Paclitaxel
9
lenvatinib
7
Carboplatin
6
belzutifan
5
Saline Solution
4
Pemetrexed
4
Oxaliplatin
4
Fluorouracil
4
Leucovorin
3
Etoposide
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Surgical Procedures, Operative
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Trastuzumab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled